CH626057A5 - - Google Patents

Download PDF

Info

Publication number
CH626057A5
CH626057A5 CH334576A CH334576A CH626057A5 CH 626057 A5 CH626057 A5 CH 626057A5 CH 334576 A CH334576 A CH 334576A CH 334576 A CH334576 A CH 334576A CH 626057 A5 CH626057 A5 CH 626057A5
Authority
CH
Switzerland
Prior art keywords
oxime
compounds
salts
aminoethyl
pharmaceutically acceptable
Prior art date
Application number
CH334576A
Other languages
German (de)
English (en)
Inventor
Hendricus Bernardus Anto Welle
Volkert Claassen
Original Assignee
Duphar Int Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res filed Critical Duphar Int Res
Publication of CH626057A5 publication Critical patent/CH626057A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CH334576A 1975-03-20 1976-03-17 CH626057A5 (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (1)

Publication Number Publication Date
CH626057A5 true CH626057A5 (en:Method) 1981-10-30

Family

ID=19823424

Family Applications (4)

Application Number Title Priority Date Filing Date
CH334576A CH626057A5 (en:Method) 1975-03-20 1976-03-17
CH154181A CH629761A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.
CH154081A CH629477A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.
CH153981A CH629184A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.

Family Applications After (3)

Application Number Title Priority Date Filing Date
CH154181A CH629761A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.
CH154081A CH629477A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.
CH153981A CH629184A5 (de) 1975-03-20 1981-03-06 Verfahren zur herstellung neuer oximaetherverbindungen.

Country Status (27)

Country Link
US (1) US4085225A (en:Method)
JP (1) JPS6026776B2 (en:Method)
AR (2) AR211011A1 (en:Method)
AT (1) AT340895B (en:Method)
AU (1) AU505358B2 (en:Method)
BE (1) BE839744A (en:Method)
CA (1) CA1076142A (en:Method)
CH (4) CH626057A5 (en:Method)
DD (1) DD128332A5 (en:Method)
DE (1) DE2610886A1 (en:Method)
DK (1) DK144942C (en:Method)
ES (1) ES446192A1 (en:Method)
FI (1) FI61875C (en:Method)
FR (1) FR2304336A1 (en:Method)
GB (1) GB1535226A (en:Method)
GR (1) GR60052B (en:Method)
HU (1) HU171030B (en:Method)
IE (1) IE43768B1 (en:Method)
IL (1) IL49238A (en:Method)
IT (1) IT1063064B (en:Method)
MX (1) MX9203723A (en:Method)
NL (1) NL7503310A (en:Method)
PL (3) PL101951B1 (en:Method)
SE (1) SE410312B (en:Method)
SU (3) SU635867A3 (en:Method)
YU (1) YU39345B (en:Method)
ZA (1) ZA761434B (en:Method)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
AU6776196A (en) * 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response
IN182588B (en:Method) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (en:Method) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
WO2001080845A2 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
CA2462903C (en) * 2001-10-12 2011-09-20 Serenix Pharmaceuticals, Llc Beta-lactamyl vasopressin v1a antagonists
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
JP2008538573A (ja) 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
AR056979A1 (es) * 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofuranos y usos de los mismos
US20060252825A1 (en) * 2005-04-22 2006-11-09 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
US7402687B2 (en) 2005-04-22 2008-07-22 Wyeth Dihydrobenzofuran derivatives and uses thereof
CA2614289A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
PL1910346T3 (pl) * 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
NZ564789A (en) * 2005-07-22 2010-07-30 Myriad Genetics Inc High drug load formulations and dosage forms
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT2491038T (pt) 2009-10-23 2016-07-14 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disubstituídos como modeladores de recetores de orexina
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
ES2858499T3 (es) 2010-07-01 2021-09-30 Azevan Pharmaceuticals Inc Compuestos para su uso en el tratamiento de trastorno explosivo intermitente
BR112013023810A2 (pt) 2011-03-17 2016-12-13 Lupin Ltd composições farmacêuticas de liberação controlada de inibidores seletivos da recaptação de serotonina
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
WO2014178064A2 (en) * 2013-04-03 2014-11-06 Zcl Chemicals Limited "an improved process for the preparation of fluvoxamine maleate"
CN106456578B (zh) 2014-02-07 2020-02-18 匈牙利科学院大学及其他机构附属研究所 Sigma-1受体激动剂化合物的用途
SG10202001065SA (en) 2014-03-28 2020-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
MY197558A (en) 2016-03-10 2023-06-23 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US12239125B2 (en) 2016-11-24 2025-03-04 SigmaDrugs Kutató Korlátolt Felelsség Társaság Compositions for organ preservation
EP3681871A4 (en) 2017-09-15 2021-05-26 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BRAIN DAMAGE
KR20220049526A (ko) 2019-07-19 2022-04-21 바이오엑셀 테라퓨틱스 인코포레이티드 비-진정성 덱스메데토미딘 치료 양생법
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
CH629477A5 (de) 1982-04-30
MX9203723A (es) 1992-07-01
DK115976A (da) 1976-09-21
FI61875C (fi) 1982-10-11
PL100052B1 (pl) 1978-08-31
SU620206A3 (ru) 1978-08-15
CH629184A5 (de) 1982-04-15
IE43768L (en) 1976-09-20
SU635867A3 (ru) 1978-11-30
CH629761A5 (de) 1982-05-14
JPS51125345A (en) 1976-11-01
NL7503310A (nl) 1976-09-22
SE410312B (sv) 1979-10-08
AU505358B2 (en) 1979-11-15
ES446192A1 (es) 1977-10-01
IL49238A0 (en) 1976-05-31
HU171030B (hu) 1977-10-28
GB1535226A (en) 1978-12-13
ATA195476A (de) 1977-05-15
SE7603341L (sv) 1976-09-21
DE2610886C2 (en:Method) 1987-09-24
YU71476A (en) 1982-10-31
YU39345B (en) 1984-10-31
DD128332A5 (de) 1977-11-09
PL100614B1 (pl) 1978-10-31
SU645559A3 (ru) 1979-01-30
FI760699A7 (en:Method) 1976-09-21
DE2610886A1 (de) 1976-10-07
PL101951B1 (pl) 1979-02-28
JPS6026776B2 (ja) 1985-06-25
IE43768B1 (en) 1981-05-20
AR211153A1 (es) 1977-10-31
IT1063064B (it) 1985-02-11
GR60052B (en) 1978-04-04
BE839744A (fr) 1976-09-20
FR2304336B1 (en:Method) 1979-09-28
AT340895B (de) 1978-01-10
CA1076142A (en) 1980-04-22
AU1214776A (en) 1977-09-22
DK144942B (da) 1982-07-12
ZA761434B (en) 1977-10-26
US4085225A (en) 1978-04-18
IL49238A (en) 1978-08-31
AR211011A1 (es) 1977-10-14
FI61875B (fi) 1982-06-30
DK144942C (da) 1982-12-06
FR2304336A1 (fr) 1976-10-15

Similar Documents

Publication Publication Date Title
CH626057A5 (en:Method)
CH616676A5 (en:Method)
CH615677A5 (en:Method)
DE2305092C2 (en:Method)
CH622507A5 (en) Process for the preparation of 1,4-dihydropyridines
CH626062A5 (en:Method)
CH622501A5 (en:Method)
DE2610679C2 (de) Sulfinylgruppenhaltige Oximätherderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
CH626056A5 (en:Method)
DE2353160C2 (de) 5-Phenyl-2,3-dihydro-1H-1,4-benzodiazepine, ihre Säureadditionssalze und diese Verbindungen enthaltende Arzneimittel
DE2034588C3 (de) 6,7-Dimethoxy-4-benzylisochinoline, Verfahren zu ihrer Herstellung und Arzneimittel
DD148633A5 (de) Verfahren zur herstellung von hexahydro-1,4-oxazepinen
DE2348577A1 (de) L-amino-4-phenyltetralin-derivate und diese enthaltende pharmazeutische zubereitung
DE2244737B2 (de) H-o-ChlorphenyD-2-tert-butylaminoäthanol, Verfahren zu dessen Herstellung und Arzneimittel auf dessen Basis
DE2421549A1 (de) Naphthalinderivate, verfahren zu ihrer herstellung und arzneimittel
DE2615129A1 (de) Tripeptide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE69621706T2 (de) Verwendung von Piperazinverbindungen als narkotische Antagonisten
DE2003353B2 (de) Phenylisopropylaminoäthanol-Derivate, deren Herstellungsverfahren und Arzneimittel auf deren Basis
DE2538593C3 (de) m-Trifluormethylthio-phenäthylaminderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2810482A1 (de) 1-phenyl-2- eckige klammer auf (n-alkyl)-amino eckige klammer zu -propan-1,3-diole, solche enthaltende arzneimittel und verfahren zur herstellung derselben
AT278785B (de) Verfahren zur Herstellung von neuen Piperidinderivaten und ihren Salzen
DE2022790C3 (de) 10-Methyl-5-[ (4-Methylpiperazino)-acetyl J-5,10dihydro-llH-dibenzo [b,e ] [1,4 ] diazepin-11-on, ein Verfahren zu dessen Herstellung sowie dieses enthaltende Arzneimittel
DE2518514A1 (de) 1,3,4-trimethyl-2-(3,4,5-trimethoxybenzyl)-1,2,5,6-tetrahydropyridin, verfahren zu seiner herstellung sowie es enthaltende arzneimittel
CH454147A (de) Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2538593B2 (de) M-trifluormethylthio-phenaethylaminderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Legal Events

Date Code Title Description
PL Patent ceased
SPCF Supplementary protection certificate filed

Free format text: IKS 44603/830713, 960221

SPCG Supplementary protection certificate granted

Free format text: IKS 44603/830713, 960221, EXPIRES:19980713